... was admitted to the hospital for irregular vaginal bleeding after menopause and performed an endometrial biopsy. Pathological of the scrapings suggested malignant melanoma. She subsequently underwent a radical surgery. The final pathology diagnosis was primary malignant melanoma of endometrium, and BRAF gene...

... prognosis. Case Presentation: We present the case of a 61-year-old female with anal canal melanoma and lung, liver, pelvic and central nervous system (CNS) metastasis, BRAF V600E mutated. Combined BRAF/MEK inhibition and CNS radiation therapy were able to achieve excellent local and distant disease control...

...Duna Barakeh; Afaf Alsolami; Malak Abedalthagafi Ameloblastic fibrosarcoma (AFS) is considered a malignant progression resulting from dysplastic changes in an ameloblastic fibroma (AF). Both tumors are extremely rare, with only a few cases reported in the scientific literature. Notably, BRAF...

...Hiroshi Kato; Shinji Kano; Yukiko Yasui; Yuka Nojiri; Maki Yoshimitsu; Motoki Nakamura; Akimichi Morita The most important driver gene in malignant melanoma is the BRAF mutation, and molecularly targeted therapies targeting mutations, mainly V600E and V600k, are used in clinical practice...

... with the coexistence of KRAS and BRAF mutations in hepatic metastases and the presence of the BRAF V600E in the primary tumour. It is unclear whether the lack of response was due to BRAF mutations, but the data suggest that mutated BRAF confers resistance to anti-epidermal growth factor receptor therapy. In our...

...Shehab F. Mohamed; Feryal Helmi; Susanna El-Akiki; Halima El Omri; Abdulqadir Nashwan; Mohamed A. Yassin Hairy cell leukemia (HCL) is rare type of leukemia. This neoplasm is well-known to present with pancytopenia and splenomegaly. HCL is associated with BRAF mutation in 100% of cases. It is also...

...Fedor V. Moiseyenko; Vitaliy V. Egorenkov; Mikhail M. Kramchaninov; Elizaveta V. Artemieva; Svetlana N. Aleksakhina; Maxim M. Holmatov; Vladimir M. Moiseyenko; Evgeny N. Imyanitov Vemurafenib has been developed to target common BRAF mutation V600E. It also exerts activity towards some but not all...

..., other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof...

... Malignant papillary thyroid carcinoma BRAF Struma ovarii is a rare ovarian neoplasm categorized as a monodermal teratoma and is composed, either exclusively or predominantly, of thyroid tissue [ 1 ]. These lesions represent 0.5–1% of all ovarian tumors and 2–5% of ovarian teratomas [ 2 ]. Most...

... kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50% of melanomas harbor activating BRAF mutations, with over 90% being the V600E mutation. Objective: The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico...